Corrections to Data Representations in Figures

Background

Accurate data representation in clinical research is crucial for guiding treatment decisions in oncology. This correction emphasizes the importance of precision in reporting clinical trial data.

Data Highlights

No numerical or trial data is presented in the article.

Key Findings

• The upper bound of the 95% CI for the hazard ratio in Figure 1A was corrected from 1.75 to 1.90 for the study by Zhong et al.
• The citation for the last study in Figure 1A was changed from reference number 33 to 32 for Lu et al.
• The citation in Figure 3A for Zhou et al. was corrected from reference number 17 to 16.

Clinical Implications

Clinicians should be aware of the potential for errors in published figures that may influence treatment decisions. It is essential to refer to corrected versions of studies to ensure accurate understanding of clinical data.

Conclusion

The corrections made to the figures in this article highlight the necessity for vigilance in data representation in clinical research. Accurate reporting is vital for informed clinical decision-making.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Erratum: 3D Reconstruction from Microscopic Imaging for Computer-Assisted Eye Surgery
3. Bone Marrow Transplantation — Amendment: Utilizing Cubic Splines to Analyze Connections Between Continuous Variables and Outcomes: A Clinician's Guide
4. European Radiology — Reevaluation of a Decade of Gadolinium Retention and Deposition: Insights from ESMRMB-GREC
5. Erratum: Comparing the "true" acetabular anteversion angle (AV angle) using 2D CT and 3D modeling techniques
6. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology
7. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial - PubMed
8. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study | Journal of Clinical Oncology